Mechanical Affective Touch Therapy for Anxiety Disorders: Feasibility, Clinical Outcomes, and Electroencephalography Biomarkers From an Open-Label Trial.

Autor:	Carpenter LL; Neuromodulation Research Facility, TMS Clinic, Butler Hospital, Providence, RI, United States.; Department of Psychiatry and Human Behavior, The Warren Alpert Medical School of Brown University, Providence, RI, United States., Kronenberg EF; Neuromodulation Research Facility, TMS Clinic, Butler Hospital, Providence, RI, United States., Tirrell E; Neuromodulation Research Facility, TMS Clinic, Butler Hospital, Providence, RI, United States., Kokdere F; Neuromodulation Research Facility, TMS Clinic, Butler Hospital, Providence, RI, United States.; Department of Psychiatry and Human Behavior, The Warren Alpert Medical School of Brown University, Providence, RI, United States., Beck QM; Neuromodulation Research Facility, TMS Clinic, Butler Hospital, Providence, RI, United States., Temereanca S; Department of Neuroscience, Brown University, Providence, RI, United States., Fukuda AM; Neuromodulation Research Facility, TMS Clinic, Butler Hospital, Providence, RI, United States.; Department of Psychiatry and Human Behavior, The Warren Alpert Medical School of Brown University, Providence, RI, United States., Garikapati S; Affect Neuro Inc., Brooklyn, NY, United States., Hagberg S; Affect Neuro Inc., Brooklyn, NY, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in psychiatry [Front Psychiatry] 2022 Apr 22; Vol. 13, pp. 877574. Date of Electronic Publication: 2022 Apr 22 (Print Publication: 2022).
DOI:	10.3389/fpsyt.2022.877574
Abstrakt:	Background: Most external peripheral nerve stimulation devices designed to alter mood states use electrical energy, but mechanical stimulation for activation of somatosensory pathways may be harnessed for potential therapeutic neuromodulation. A novel investigational device for Mechanical Affective Touch Therapy (MATT) was created to stimulate C-tactile fibers through gentle vibrations delivered by piezoelectric actuators on the bilateral mastoid processes. Methods: 22 adults with anxiety disorders and at least moderate anxiety symptom severity enrolled in an open-label pilot trial that involved MATT self-administration using a simple headset at home at least twice per day for 4 weeks. Resting EEG data were acquired before and after a baseline MATT session and again before the final MATT session. Self-report measures of mood and anxiety were collected at baseline, week 2, and week 4, while interoception was assessed pre- and post-treatment. Results: Anxiety and depressive symptoms improved significantly from baseline to endpoint, and mindfulness was enhanced. EEG metrics confirmed an association between acute MATT stimulation and oscillatory power in alpha and theta bands; symptom changes correlated with changes in some metrics. Conclusion: Open-label data suggest MATT is a promising non-invasive therapeutic approach to anxiety disorders that warrants further development. Competing Interests: Collection of the data for this investigator-designed study was supported by Affect Neuro Inc., developer of MATT therapy, via a contract with Butler Hospital that covered research staff effort, subject payments, and other costs associated with data collection and analysis. In the past 2 years, LC served as a consultant to Neuronetics, Inc., Nexstim PLC, Affect Neuro Inc., Neurolief Ltd., Sage Therapeutics, Otsuka, Sunovion, and Janssen Pharmaceuticals, Inc. and received research support (contracts to Butler Hospital) from Neuronetics, Inc., NeoSync, Inc., Nexstim PLC, Affect Neuro Inc., Neurolief Ltd., and Janssen Pharmaceuticals, Inc. SG is an employee of Affect Neuro Inc. and has a patent No. 17/026,26 pending to Affect Neuro Inc. SH is an employee of Affect Neuro Inc. and has pending patents Nos. 17/026,26 and 16/241,227 to Affect Neuro Inc., and patent 10,786,666 issued to Affect Neuro Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Carpenter, Kronenberg, Tirrell, Kokdere, Beck, Temereanca, Fukuda, Garikapati and Hagberg.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu